300 related articles for article (PubMed ID: 32466400)
1. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics.
Rinaldi L; Nevola R; Franci G; Perrella A; Corvino G; Marrone A; Berretta M; Morone MV; Galdiero M; Giordano M; Adinolfi LE; Sasso FC
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466400
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals.
Syed T; Fazili J; Ali IA; Zhao D; Hughes D; Mahmood S
Cureus; 2018 Jun; 10(6):e2843. PubMed ID: 30280052
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness.
Dajti E; Marasco G; Ravaioli F; Colecchia L; Ferrarese A; Festi D; Colecchia A
JHEP Rep; 2021 Jun; 3(3):100289. PubMed ID: 34095798
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
[TBL] [Abstract][Full Text] [Related]
9. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.
Li DK; Chung RT
Cancer; 2015 Sep; 121(17):2874-82. PubMed ID: 26079399
[TBL] [Abstract][Full Text] [Related]
10. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.
Lleo A; Aglitti A; Aghemo A; Maisonneuve P; Bruno S; Persico M;
Dig Liver Dis; 2019 Feb; 51(2):310-317. PubMed ID: 30473220
[TBL] [Abstract][Full Text] [Related]
11. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
12. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
14. Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals.
Perez S; Gal-Tanamy M
Methods Mol Biol; 2019; 1911():191-207. PubMed ID: 30593627
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis.
Galati G; Muley M; Viganò M; Iavarone M; Vitale A; Dell'Unto C; Lai Q; Cabibbo G; Sacco R; Villa E; Trevisani F
Expert Opin Drug Saf; 2019 Jul; 18(7):603-610. PubMed ID: 31067134
[TBL] [Abstract][Full Text] [Related]
16. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
18. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk.
Su F; Ioannou GN
Curr Hepatol Rep; 2018 Dec; 17(4):377-384. PubMed ID: 30923667
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
[TBL] [Abstract][Full Text] [Related]
20. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus.
Yasui Y; Kurosaki M; Komiyama Y; Takada H; Tamaki N; Watakabe K; Okada M; Wang W; Shimizu T; Kubota Y; Higuchi M; Takaura K; Tsuchiya K; Nakanishi H; Takahashi Y; Itakura J; Enomoto N; Izumi N
Hepatol Res; 2018 Dec; 48(13):1131-1139. PubMed ID: 30030872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]